Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zentalis Pharmaceuticals Inc 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 USA

https://zentalis.com Employees: 168 P: 858-263-4333

Description:

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK.

Key Statistics

Overview:

Market Capitalization, $K 213,795
Enterprise Value, $K 185,755
Shares Outstanding, K 71,265
Annual Sales, $ 0 K
Annual Net Income, $ -292,190 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -88,280 K
EBIT, $ -220,560 K
EBITDA, $ -232,330 K
60-Month Beta 1.84
% of Insider Shareholders 3.60%
Float, K 68,699
% Float 96.40%
Short Volume Ratio 0.50

Growth:

1-Year Return -77.88%
3-Year Return -96.43%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.56 on 11/12/24
Next Earnings Date 11/18/24
Earnings Per Share ttm -2.72
EPS Growth vs. Prev Qtr 54.84%
EPS Growth vs. Prev Year 29.11%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ZNTL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -43.91%
Return-on-Assets % -34.96%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 5.25
Price/Cash Flow N/A
Price/Book 0.59
Book Value/Share 5.39
Interest Coverage -3.30
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar